Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Mar 8th (reported today) which has an aggregated short interest worth USD19.8bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in ANZ, BHP, IDP Education, Woodside Energy, Macquarie, CSL, Aristocrat Leisu.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Mar 8th (reported today) which has an aggregated short interest worth USD19.8bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in ANZ, BHP, IDP Education, Woodside Energy, Macquarie, CSL, Aristocrat Leisu.


ASX Short Interest Weekly (Mar 8th): ANZ, BHP, IDP Education, Woodside Energy, Macquarie, CSL

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Feb 16th (reported today) which has an aggregated short interest worth USD18.0bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Seek, Origin Energy, Woodside Energy, ANZ, Qantas Airways.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Feb 16th (reported today) which has an aggregated short interest worth USD18.0bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Seek, Origin Energy, Woodside Energy, ANZ, Qantas Airways.


ASX Short Interest Weekly (Feb 16th): Seek, Origin Energy, Woodside Energy, ANZ, Qantas Airways

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Feb 9th (reported today) which has an aggregated short interest worth USD18.1bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest weekly changes in ANZ, CSL, Telstra.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Feb 9th (reported today) which has an aggregated short interest worth USD18.1bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest weekly changes in ANZ, CSL, Telstra.


ASX Short Interest Weekly (Feb 9th): ANZ, CSL, Telstra

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a> has reported strong financial performance in H1FY24, with revenue and net profit growing 11% and 20%, YoY, respectively. Growth was mainly driven by immunoglobulins franchise.</li>
<li>CSL reaffirmed FY24 guidance. Revenue growth is anticipated to be 9–11% YoY at constant currency. NPATA is anticipated to be $2.9–3.0B at constant currency, up 13–17% YoY.</li>
<li>The company is confident to deliver double-digit earnings growth over the medium term, citing strong demand for immunoglobulins and successful initiatives in plasma collections that are enhancing efficiencies.</li>
</ul>



CSL Ltd (CSL AU) has reported strong financial performance in H1FY24, with revenue and net profit growing 11% and 20%, YoY, respectively. Growth was mainly driven by immunoglobulins franchise.
CSL reaffirmed FY24 guidance. Revenue growth is anticipated to be 9–11% YoY at constant currency. NPATA is anticipated to be $2.9–3.0B at constant currency, up 13–17% YoY.
The company is confident to deliver double-digit earnings growth over the medium term, citing strong demand for immunoglobulins and successful initiatives in plasma collections that are enhancing efficiencies.


CSL Ltd (CSL AU): Double-Digit Sales and Profit Growth in H1FY24 Led by Immunoglobulin Franchise

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Feb 2nd (reported today) which has an aggregated short interest worth USD18.3bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Fortescue, Rio Tinto, Wisetech Global.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Feb 2nd (reported today) which has an aggregated short interest worth USD18.3bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Fortescue, Rio Tinto, Wisetech Global.


ASX Short Interest Weekly (Feb 2nd): Fortescue, Rio Tinto, Wisetech Global

Australia

CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CSL Ltd (CSL AU)

ASX Short Interest Weekly (Mar 8th): ANZ, BHP, IDP Education, Woodside Energy, Macquarie, CSL

We analyzed ASX short interest report for the past week and highlight short interest changes in ANZ, BHP, IDP Education, Woodside Energy,...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Feb 16th): Seek, Origin Energy, Woodside Energy, ANZ, Qantas Airways

We analyzed ASX short interest report for the past week and highlight short interest changes in Seek, Origin Energy, Woodside Energy, ANZ, Qantas...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Feb 9th): ANZ, CSL, Telstra

We analyzed ASX short interest report for the past week and highlight short interest weekly changes in ANZ, CSL, Telstra.

Ke Yan, CFA, FRM

CSL Ltd (CSL AU): Double-Digit Sales and Profit Growth in H1FY24 Led by Immunoglobulin Franchise

In H1FY24, CSL reported 23% YoY growth in revenue from Immunoglobulin. The company has reaffirmed FY24 guidance. FY24 revenue and NPATA are...

Tina Banerjee

ASX Short Interest Weekly (Feb 2nd): Fortescue, Rio Tinto, Wisetech Global

We analyzed ASX short interest report for the past week and highlight short interest changes in Fortescue, Rio Tinto, Wisetech Global.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)